Welcome to the website of the UK Chemotherapy Partnership – aiming to improve the quality and safety of chemotherapy delivery by sharing information, expertise and opinion. We open the door on the latest developments in chemotherapy service provision and give you access to NHS experts and their documentation to help you develop and improve your own service.

Chemotherapy service

Chemotherapy delivery can be complex and challenging. These are some of the practice innovations and developments within the UK aiming to improve the patient experience.

March 2016
Events & meetings

UKCP Systemic-Anti Cancer Therapy Masterclass
Programme to follow.  


Coming soon. We are very excited to announce this new online educational resource. It will initially include 6 modules on cancer and chemotherapy.

Our videos

Healthcare professionals sharing experiences of service developments, including patient information videos for patients embarking on the treatment pathway.

What's new

Achieving World-Class Outcomes-A Strategy for England 2015-2020

Five year plan to radically improve cancer outcomes.

2015 ASCO Annual Meeting-Highlights

Highlights from the 2015 ASCO Annual Meeting-Illumination & Innovation; Transforming Data into Learning

Recovery Package-Cancer Nursing Partnership

The CNP is working to roll out the Recovery Package

Understanding Cancer E-Learning

Understanding Cancer was launched in April 2012.


Latest news

Delayed exposure to common infections causes acute leukaemia of childhood

Acute leukaemia is the most common cancer in childhood and the incidence is increasing especially in socio economic advanced countries. Infection as a trigger of leukaemia development in children has been controversially discussed since decades and...

The more the T-lymphocytes differ, the more effectively they fight against leukaemia

Adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (r/r ALL) have a poor prognosis despite intense salvage treatments. Recent reports have shown that Blinatumomab (Blin) can induce high remission rates in these...

Existing drugs could benefit patients with bone cancer, genetic study suggests

A subgroup of patients with osteosarcoma - a form of bone cancer - could be helped by an existing drug, suggest scientists from the Wellcome Trust Sanger Institute and their collaborators at University College London Cancer Institute and the Royal...

Cerdulatinib demonstrates rapid tumour responses in a phase 2 study for relapsed/refractory NHL

Cerdulatinib is an oral, dual Syk-JAK inhibitor with a unique mechanism of action. It inhibits two key signaling pathways that promote cancer cell growth in certain haematologic malignancies: the B-cell receptor pathway via Syk and key cytokine receptors...

Scientists uncover potential mechanism for HPV-induced skin cancer

Scientists have identified a molecular pathway by which some types of human papilloma virus (HPV) might increase the risk of skin cancer, particularly in people with the rare genetic disorder epidermodysplasia verruciformis (EV). The novel pathway is...